Yu Y Bruce
Department of Pharmaceutics and Pharmaceutical Chemistry, Department of Bioengineering, University of Utah, Salt Lake City, UT 84108, USA.
J Drug Target. 2006 Dec;14(10):663-9. doi: 10.1080/10611860600957887.
The history and current status of fluorocarbon nanoparticles in biomedicine is briefly reviewed. The deficiencies of current fluorocarbon nanoparticle formulations are highlighted. Strategies to remedy such deficiencies and to functionalize fluorocarbon nanoparticles are presented. Potential applications of fluorocarbon nanoparticles as multifunctional drug delivery vehicles are discussed. The strength of fluorocarbon nanoparticles as drug delivery vehicles is that they integrate drug delivery with non-invasive MR imaging so that the biodistribution of the pharmaceutical entity (drug + delivery vehicle) can be monitored in real time. This, in turn, permits the physician to adjust treatment plan for each patient based on his/her actual response to the ongoing treatment.
简要回顾了碳氟化合物纳米颗粒在生物医学领域的历史和现状。重点强调了当前碳氟化合物纳米颗粒制剂的不足之处。提出了弥补这些不足以及使碳氟化合物纳米颗粒功能化的策略。讨论了碳氟化合物纳米颗粒作为多功能药物递送载体的潜在应用。碳氟化合物纳米颗粒作为药物递送载体的优势在于,它们将药物递送与非侵入性磁共振成像相结合,从而可以实时监测药物实体(药物+递送载体)的生物分布。反过来,这使医生能够根据每位患者对正在进行的治疗的实际反应来调整治疗方案。